AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.
Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patient
Dementia with Lewy bodies (DLB) may not be as well-known as other forms like Alzheimer’s, but is just as devastating, so the discovery that commonly used drugs may reduce the risk of the di
An artificial intelligence-powered blood test that may be able to predict Parkinson’s disease several years before symptoms start to develop could allow earlier treatment and help guide the
The US Senate has joined the House of Representatives in approving the first-ever federal bill dedicated to ending Parkinson’s disease, modelled on similar legislation for